Jaguar Health Files 8-K/A Amendment

Ticker: JAGX · Form: 8-K/A · Filed: 2025-04-25T00:00:00.000Z

Sentiment: neutral

Topics: amendment, financial-obligation, equity-sale

Related Tickers: JAGX

TL;DR

Jaguar Health amended its 8-K filing regarding material agreements and equity sales.

AI Summary

Jaguar Health, Inc. filed an 8-K/A on January 29, 2025, to amend a previous filing. The amendment pertains to the entry into a material definitive agreement, the creation of a direct financial obligation, and unregistered sales of equity securities. Specific details regarding the agreement, financial obligation, and equity sales are not fully elaborated in the provided text but are the subject of this amendment.

Why It Matters

This filing indicates Jaguar Health is amending previous disclosures related to significant financial agreements and equity transactions, which could impact its financial obligations and shareholder structure.

Risk Assessment

Risk Level: medium — Amendments to material definitive agreements and financial obligations can signal changes in a company's financial health or strategic direction.

Key Players & Entities

FAQ

What specific material definitive agreement is Jaguar Health amending?

The provided text does not specify the details of the material definitive agreement being amended, only that an amendment is being filed.

What is the nature of the direct financial obligation or off-balance sheet arrangement being amended?

The filing indicates an amendment related to the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement, but the specific details are not provided in this excerpt.

What unregistered sales of equity securities are being amended?

The filing notes an amendment concerning unregistered sales of equity securities, but the specifics of these sales are not detailed in the provided text.

What is the purpose of filing an 8-K/A instead of an initial 8-K?

An 8-K/A is filed to amend a previously filed Current Report on Form 8-K, indicating that information previously reported needs to be corrected or supplemented.

When was the original event that this 8-K/A is amending?

The filing states the date of the earliest event reported is January 29, 2025, which is the date this 8-K/A is filed, implying the original event or reporting was around this date.

From the Filing

0000950170-25-058837.txt : 20250425 0000950170-25-058837.hdr.sgml : 20250425 20250425165658 ACCESSION NUMBER: 0000950170-25-058837 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20250129 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250425 DATE AS OF CHANGE: 20250425 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jaguar Health, Inc. CENTRAL INDEX KEY: 0001585608 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36714 FILM NUMBER: 25875001 BUSINESS ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-371-8300 MAIL ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Jaguar Animal Health, Inc. DATE OF NAME CHANGE: 20130830 8-K/A 1 jagx-20250129.htm 8-K/A 8-K/A true 0001585608 0001585608 2025-01-29 2025-01-29   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K/A   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2025     Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter)     Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)           200 Pine Street Suite 400   San Francisco , California   94104 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s Telephone Number, Including Area Code: (415) 371-8300     (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, Par Value $0.0001 Per Share   JAGX   The Nasdaq Stock Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   Explanatory Note On February 4, 2025, Jaguar Health, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Report”) with the U.S. Securities and Exchange Commission, which included, among other disclosures, information regarding certain agreements entered into by the Company. The Company is filing this Amendment No. 1 on Form 8-K/A (the “Amendment”) solely to correct the Date of Report (

View on Read The Filing